Advances in Patient-Reported Outcomes: The NIH PROMIS(®) Measures.
Advances in Patient-Reported Outcomes: The NIH PROMIS(®) Measures.
复制标题
DOI：
10.13063/2327-9214.1015
复制
发表时间：
2013
期刊：
影响因子：
--
通讯作者：
Forrest CB
中科院分区：
文献类型：
--
作者：
Broderick JE;DeWitt EM;Rothrock N;Crane PK;Forrest CB
患者报告结果(PRO)是对患者的症状、功能和与健康相关的生活质量的问卷测量。它们的设计目的是提供重要的临床信息，这些信息通常无法通过客观的医学测试获得。2004年，美国国立卫生研究院发起了一项研究计划，通过发展最先进的专业人员来改善临床研究事业。NIH患者报告结果评估系统(PROMIS)和评估中心就是这一倡议的产物。成人、儿科和父母代用题库已经通过使用现代心理测量学方法开发出来，产生快速、准确的测量。PROMIS目前提供了使用简明形式和计算机自适应测试方法评估身体、心理和社会健康的工具。PROMIS工具正被用于临床试验和转译研究。它们还被引入临床医学，以评估广泛的疾病结果。美国最近的立法发展支持做出更大努力，纳入患者的健康经历报告，以评估治疗结果，参与共同决策，并确定治疗重点。在评估药物和医疗器械方面，专业人员得到了美国食品和药物管理局(FDA)越来越多的关注。最近呼吁进行比较有效性研究的呼声更倾向于将专业人士纳入其中。PROS还可以潜在地提高护理质量和疾病结果，为比较有效性研究提供以患者为中心的评估，并实现跨提供者和医疗系统跟踪结果的通用指标。
Patient-reported outcomes (PRO) are questionnaire measures of patients’ symptoms, functioning, and health-related quality of life. They are designed to provide important clinical information that generally cannot be captured with objective medical testing. In 2004, the National Institutes of Health launched a research initiative to improve the clinical research enterprise by developing state-of-the-art PROs. The NIH Patient-Reported Outcomes Measurement System (PROMIS) and Assessment Center are the products of that initiative. Adult, pediatric, and parent-proxy item banks have been developed by using contemporary psychometric methods, yielding rapid, accurate measurements. PROMIS currently provides tools for assessing physical, mental, and social health using short-form and computer-adaptive testing methods. The PROMIS tools are being adopted for use in clinical trials and translational research. They are also being introduced in clinical medicine to assess a broad range of disease outcomes. Recent legislative developments in the United States support greater efforts to include patients’ reports of health experience in order to evaluate treatment outcomes, engage in shared decision-making, and prioritize the focus of treatment. PROs have garnered increased attention by the Food and Drug Administration (FDA) for evaluating drugs and medical devices. Recent calls for comparative effectiveness research favor inclusion of PROs. PROs could also potentially improve quality of care and disease outcomes, provide patient-centered assessment for comparative effectiveness research, and enable a common metric for tracking outcomes across providers and medical systems.